Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954796 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02954796: Clinical Trial Phase 1 study, sponsored by Seagen.
NCT02954796 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02954796, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.
Interventions
- DRUG SGN-CD352A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-07-17 |
| Phase | Phase 1 |
Why NCT02954796 stopped before completion
NCT02954796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which SGN-CD352A is the first listed.
NCT02954796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02954796 about?
NCT02954796 is a clinical study titled "A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma". This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.
What is the current status of trial NCT02954796?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2016-12. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT02954796?
The interventions under investigation include: SGN-CD352A (DRUG).
Who is sponsoring clinical trial NCT02954796?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02954796's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia